Calithera Biosciences is a biotechnology business based in the US. Calithera Biosciences shares (CALA) are listed on the PINK and all prices are listed in US Dollars. Its last market close was $0.01 – an increase of 4.23% over the previous week. Calithera Biosciences employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.01 |
|---|---|
| 52-week range | $0.00 - $0.05 |
| 50-day moving average | $0.01 |
| 200-day moving average | $0.02 |
| Wall St. target price | $5.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-7.94 |
Historical closes compared with the close of $0.0074 from 2024-11-22
| 1 week (2024-11-18) | 4.23% |
|---|---|
| 1 month (2024-10-25) | 23.33% |
| 3 months (2024-08-22) | N/A |
| 6 months (2024-05-24) | -63.00% |
| 1 year (2023-11-24) | -75.33% |
|---|---|
| 2 years (2022-11-25) | -99.63% |
| 3 years (2021-11-24) | 17.76 |
| 5 years (2019-11-25) | 91.6 |
| Gross profit TTM | $-42,705,000 |
|---|---|
| Return on assets TTM | -56.29% |
| Return on equity TTM | -114.14% |
| Profit margin | 0% |
| Book value | $-0.40 |
| Market Capitalization | $36,056 |
TTM: trailing 12 months
We're not expecting Calithera Biosciences to pay a dividend over the next 12 months.
Calithera Biosciences's shares were split on a 1:20 basis on 14 June 2022 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Calithera Biosciences shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Calithera Biosciences shares which in turn could have impacted Calithera Biosciences's share price.
Over the last 12 months, Calithera Biosciences's shares have ranged in value from as little as $0.0001 up to $0.05. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (PINK average) beta is 1, while Calithera Biosciences's is -1.134. This would suggest that Calithera Biosciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Calithera Biosciences has bucked the trend.
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. .
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.